Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M107,880Revenue $M18,790Net Margin (%)18.9Z-Score4.6
Enterprise Value $M114,922EPS $2.6Operating Margin %27.3F-Score6
P/E(ttm))29.4Cash Flow Per Share $0Pre-tax Margin (%)24.7Higher ROA y-yN
Price/Book23.210-y EBITDA Growth Rate %0Quick Ratio2.5Cash flow > EarningsY
Price/Sales5.65-y EBITDA Growth Rate %4.2Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-14.4ROA % (ttm)12.9Higher Current Ratio y-yY
Dividend Yield %2.5Insider Buy (3m)0ROE % (ttm)82.0Less Shares Outstanding y-yN
Payout Ratio %71.0Shares Outstanding M1,593ROI % (ttm)22.2Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJohn Paulson 2014-09-30 Buy 3.1%$52.05 - $59.62
($55.51)
$ 67.7122%New holding, 13000000 sh.13,000,000
ABBVAndreas Halvorsen 2014-09-30 Buy 2.5%$52.05 - $59.62
($55.51)
$ 67.7122%New holding, 10769105 sh.10,769,105
ABBVLee Ainslie 2014-09-30 Add1.26%$52.05 - $59.62
($55.51)
$ 67.7122%Add 46.01%4,723,578
ABBVSteve Mandel 2014-09-30 Buy 1.2%$52.05 - $59.62
($55.51)
$ 67.7122%New holding, 5247201 sh.5,247,201
ABBVGeorge Soros 2014-09-30 Add0.6%$52.05 - $59.62
($55.51)
$ 67.7122%Add 924.76%1,537,146
ABBVJohn Hussman 2014-09-30 Reduce-0.87%$52.05 - $59.62
($55.51)
$ 67.7122%Reduce -66.67%100,000
ABBVJoel Greenblatt 2014-09-30 Reduce-0.06%$52.05 - $59.62
($55.51)
$ 67.7122%Reduce -89.36%9,460
ABBVLee Ainslie 2014-06-30 Buy 2.6%$46.46 - $56.79
($52.4)
$ 67.7129%New holding, 3235133 sh.3,235,133
ABBVKen Fisher 2014-06-30 Add0.06%$46.46 - $56.79
($52.4)
$ 67.7129%Add 76.13%1,104,609
ABBVNWQ Managers 2014-06-30 Buy 0.05%$46.46 - $56.79
($52.4)
$ 67.7129%New holding, 83878 sh.83,878
ABBVJoel Greenblatt 2014-06-30 Reduce-0.11%$46.46 - $56.79
($52.4)
$ 67.7129%Reduce -61.19%88,923
ABBVGeorge Soros 2014-06-30 Reduce-0.1%$46.46 - $56.79
($52.4)
$ 67.7129%Reduce -57.14%150,000
ABBVJoel Greenblatt 2014-03-31 Add0.1%$46.83 - $53.68
($50.6)
$ 67.7134%Add 120.38%229,149
ABBVGeorge Soros 2014-03-31 Reduce-0.35%$46.83 - $53.68
($50.6)
$ 67.7134%Reduce -69.5%350,000
ABBVVanguard Health Care Fund 2014-03-31 Sold Out -0.28%$46.83 - $53.68
($50.59)
$ 67.7134%Sold Out0
ABBVKen Fisher 2014-03-31 Reduce-0.06%$46.83 - $53.68
($50.59)
$ 67.7134%Reduce -45.03%627,139
ABBVDavid Dreman 2014-03-31 Sold Out -0.02%$46.83 - $53.68
($50.6)
$ 67.7134%Sold Out0
ABBVDavid Dreman 2013-12-31 Buy 0.02%$44.52 - $54.32
($49.14)
$ 67.7138%New holding, 4572 sh.4,572
ABBVVanguard Health Care Fund 2013-12-31 Reduce-1.03%$44.52 - $54.32
($49.14)
$ 67.7138%Reduce -79.44%1,739,600
ABBVJohn Hussman 2013-12-31 Reduce-0.25%$44.52 - $54.32
($49.14)
$ 67.7138%Reduce -24.8%303,250
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABBV Andreas Halvorsen 2014-09-3010,769,1050.682.5New Buy
ABBV Steve Mandel 2014-09-305,247,2010.331.2New Buy
ABBV John Paulson 2014-09-3013,000,0000.823.1New Buy
ABBV George Soros 2014-09-301,537,1460.10.66+924.76%
ABBV Lee Ainslie 2014-09-304,723,5780.34+46.01%
ABBV Dodge & Cox 2014-09-3038,84900+6%
ABBV NWQ Managers 2014-09-3085,9480.010.06+2.47%
ABBV PRIMECAP Management 2014-09-306,454,8360.410.4+2.39%
ABBV Mario Gabelli 2014-09-3010,38200
ABBV Robert Bruce 2014-09-30231,3000.013.7
ABBV Ken Fisher 2014-09-30999,7680.060.12-9.49%
ABBV John Hussman 2014-09-30100,0000.010.49-66.67%
ABBV Joel Greenblatt 2014-09-309,46000.01-89.36%
Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HURWICH THOMAS A.VP, Controller 2014-11-24Sell1,500$67.81-0.15view
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.232.25view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.0935.18view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.2234.83view
SALEKI-GERHARDT AZITASVP, Operations 2014-03-03Sell2,443$50.2534.75view
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2014-03-03Sell4,143$50.0335.34view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-18Sell465$51.2332.17view
RICHMOND TIMOTHY J.SVP, Human Resources 2014-02-05Sell1,460$47.7841.71view
SALEKI-GERHARDT AZITASVP, Operations 2014-02-05Sell687$47.8441.53view
SALEKI-GERHARDT AZITASVP, Operations 2013-09-17Sell10,473$45.8447.71view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    Is it Time to Sell Gilead Sciences? Dec 18 2014 
    What's More Powerful Than Compound Interest? Dec 16 2014 
    T Rowe Price's Top Stakes for the Third Quarter Dec 09 2014 
    Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
    Andreas Halvorsen Joins Other Gurus in Investing in Alibaba Dec 03 2014 
    Six High-Yielding Mega-Cap Stocks Nov 25 2014 
    Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
    John Paulson's Top 5 New Holdings For Q3 Nov 21 2014 
    John Paulson's Top 5 New Holdings for Q3 Nov 21 2014 
    Facebook Among New Holdings in Steve Mandel's Portfolio Nov 20 2014 


    More From Other Websites
    U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks Dec 19 2014
    AbbVie says newly approved hepatitis C treatment costs $83,319 Dec 19 2014
    [$$] FDA Backs AbbVie's Hepatitis Treatment Dec 19 2014
    5:47 pm AbbVie confirms FDA approval of Viekira Pak for the treatment of chronic genotype 1... Dec 19 2014
    AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead? Dec 19 2014
    Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next Dec 19 2014
    FDA approves AbbVie’s hepatitis treatment Dec 19 2014
    U.S. FDA approves AbbVie all-oral hepatitis C treatment Dec 19 2014
    AbbVie: Here's How It Could Differentiate Itself From Gilead Dec 18 2014
    AbbVie Pins Hopes on Hepatitis C Treatment Dec 18 2014
    Shire considering bid for NPS Pharmaceuticals - Bloomberg Dec 17 2014
    Shire considering bid for NPS Pharmaceuticals - Bloomberg Dec 17 2014
    Shire Said to Weigh Offer for NPS as It Revisits Deals Dec 17 2014
    Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Dec 16 2014
    Will AbbVie Undercut Gilead on Hepatitis C? Dec 11 2014
    Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers Dec 11 2014
    Gilead Is Growing Fast And Its Stock Is Cheap Dec 11 2014
    Walgreens CEO announces plans to step down Dec 10 2014
    AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) Dec 10 2014
    Gilead Sciences: Still Waiting on AbbVie Dec 09 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK